These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 109501)

  • 61. A new Pseudomonas vaccine: preliminary trial on human volunteers.
    Jones RJ; Roe EA; Lowbury EJ; Miler JJ; Spilsbury JF
    J Hyg (Lond); 1976 Jun; 76(3):429-39. PubMed ID: 819576
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of antibody in infections due to Pseudomonas aeruginosa.
    Young LS
    J Infect Dis; 1974 Nov; 130 Suppl(0):S111-8. PubMed ID: 4213568
    [No Abstract]   [Full Text] [Related]  

  • 63. Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections.
    Pennington JE; Miler JJ
    Infect Immun; 1979 Sep; 25(3):1029-34. PubMed ID: 115786
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
    Cryz SJ; Sadoff JC; Cross AS; Fürer E
    Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836
    [No Abstract]   [Full Text] [Related]  

  • 65. Passive protection of mice against Pseudomonas aeruginosa by serum from recently vaccinated mice.
    Jones RJ; Lilly HA; Lowbury EJ
    Br J Exp Pathol; 1971 Jun; 52(3):264-70. PubMed ID: 4996963
    [TBL] [Abstract][Full Text] [Related]  

  • 66. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa.
    Ding B; von Specht BU; Li Y
    Vaccine; 2010 Jun; 28(25):4119-22. PubMed ID: 20433804
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Is an active immunization against pseudomonas aeruginosa in burns justifiable?].
    Zellner PR; Zwissler O; Metzger E
    Chirurg; 1975 Oct; 46(10):462-66. PubMed ID: 815075
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection.
    Gilleland HE; Gilleland LB; Staczek J; Harty RN; García-Sastre A; Palese P; Brennan FR; Hamilton WD; Bendahmane M; Beachy RN
    FEMS Immunol Med Microbiol; 2000 Apr; 27(4):291-7. PubMed ID: 10727884
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Principle of constructing polyvalent Pseudomonas aeruginosa vaccines].
    Akatova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Feb; (2):56-60. PubMed ID: 84457
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.
    Cripps AW; Peek K; Dunkley M; Vento K; Marjason JK; McIntyre ME; Sizer P; Croft D; Sedlak-Weinstein L
    Infect Immun; 2006 Feb; 74(2):968-74. PubMed ID: 16428742
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Prevention using a Pseudomonas immunoglobulin in burn patients].
    Stuttmann R; Petrovici V; Hartert M
    Infection; 1987; 15(1):80-4. PubMed ID: 3106234
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative studies on the protective potential of antisera directed against four antigenic preparations from Pseudomonas aeruginosa.
    Johnston LJ; Syeklocha D
    Can J Microbiol; 1972 Oct; 18(10):1607-11. PubMed ID: 4628185
    [No Abstract]   [Full Text] [Related]  

  • 73. Pilot study into the IgG1 and IgG2 subclass response to polyvalent Pseudomonas vaccine in burned adults.
    Frame JD; Everitt AS
    Burns; 1989 Jun; 15(3):167-70. PubMed ID: 2757766
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The efficiency of specific immunization with corpuscular vaccines in the treatment and prophylaxis of Pseudomonas aeruginosa infections of the bones.
    Denischi A; Meitert E; Cursaru A; Purghel E; Stăngulescu D; Sima F; Savulian C; Chersulick E; Petrescu AM; Costin M
    Arch Roum Pathol Exp Microbiol; 1987; 46(2):111-27. PubMed ID: 3138966
    [No Abstract]   [Full Text] [Related]  

  • 75. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Furer E; Sadoff JC; Germanier R
    Infect Immun; 1986 Apr; 52(1):161-5. PubMed ID: 3082756
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An acellular vaccine from Pseudomonas aeruginosa: homologous and crossed protection between serogroups according to Habs' classification.
    Berche P; Véron M; Fermanian J; Daoulas-Lebourdelles F; Guégen A
    Ann Microbiol (Paris); 1979; 130(2):179-88. PubMed ID: 90473
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [An acellular vaccine from Pseudomonas aeruginosa. II. -- Estimate of immuneserum protective effect by measure of bacterial clearance (author's transl)].
    Daoulas-Le Bourdelles F; Berche P; Véron M
    Ann Microbiol (Paris); 1977 Jul; 128B(1):61-71. PubMed ID: 410340
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
    Baumann U; Göcke K; Gewecke B; Freihorst J; von Specht BU
    Respir Res; 2007 Aug; 8(1):57. PubMed ID: 17683588
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevention of pseudomonas respiratory infection in a surgical intensive care unit.
    Polk HC; Borden S; Aldrete JA
    Ann Surg; 1973 May; 177(5):607-15. PubMed ID: 4634109
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.